According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

Published Date: 09 Jun 2023

Italy: Deep, long-lasting responses and sustained survival seen with fixed-duration ibrutinib plus venetoclax are maintained in high-risk patients.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

2.

Cancerous breast tissue glows in new AI-enhanced MRI images

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.

5.

Researchers identify a novel biomarker linked to renal cancer recurrence


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot